Intravascular brachytherapy: Indications and management of adverse events

被引：6

作者：

Bhargava B. ^{[1
]}

Karthikeyan G. ^{[1
]}

Tripuraneni P. ^{[2
]}

机构：

[1] Department of Cardiology, Cardiothoracic Sciences Centre, All India Institute of Medical Sci.

[2] The Scripps Clinic, La Jolla, CA

来源：

American Journal of Cardiovascular Drugs | 2004年 / 4卷 / 6期

关键词：

Target Lesion Revascularization; Restenosis Rate; Angiographic Restenosis; Late Thrombosis; Edge Failure;

D O I：

10.2165/00129784-200404060-00007

中图分类号：

学科分类号：

摘要：

Intravascular brachytherapy has become the standard of care for the treatment of coronary in-stent restenosis after repeat angioplasty. More than 5000 patients have been treated as part of various clinical trials. Based on the results of the GAMMA I trial, the START (90Sr Treatment of Angiographic Restenosis Trial), and the INHIBIT (INtimal Hyperplasia Inhibition with Beta In-stent restenosis Trial), the Checkmate® system using 192Ir, the Betacath® system using 90Sr/Y, and the Galileo® system using 32P, have been approved for the treatment of in-stent restenosis. With a better understanding and application of radiation oncology concepts to vascular brachytherapy, problems such as edge failure are being overcome. The complication of late thrombosis has also become less significant with the elimination of restenting at the brachytherapy procedure, and the prolonged use of antiplatelet therapy. There are other competing modalities in the early phases of clinical trials. The durability of results, lack of any significant long-term complications and the confirmation of the efficacy in other sites will further consolidate the role of radiation in treating in-stent restenosis. © 2004 Adis Data Information BV. All rights reserved.

引用

页码：385 / 394

页数：9

共 62 条

[1]

Casterella P.J., Restenosis: The scope of the problem, Intravascular Brachytherapy: From Theory to Practice, pp. 143-165, (2001)

[2]

Condado J.A., Waksman R., Gurdiel O., Long-term angiographic and clinical outcome after percutaneous transluminal coronary angioplasty and intracoronary radiation therapy in humans, Circulation, 96, pp. 727-732, (1997)

[3]

Condado J.A., Waksman R., Calderas C., Two-year follow-up after intracoronary gamma radiation therapy, Cardiovasc. Radiat. Med., 1, 1, pp. 30-35, (1999)

[4]

Condado J.A., Waksman R., Saucedo J.F., Et al., Five-year clinical and angiographic follow-up after intracoronary iridium-192 radiation therapy, Cardiovasc. Radiat. Med., 3, pp. 74-81, (2002)

[5]

Verin V., Urban P., Popowski Y., Et al., Feasibility of intracoronary beta-irradiation to reduce restenosis after balloon angioplasty, Circulation, 95, pp. 1138-1144, (1997)

[6]

Verin V., Popowski Y., Intraarterial beta irradiation to reduce restenosis after PTCA: Experimental and clinical experience, Herz, 6, pp. 347-355, (1998)

[7]

Teirstein P.S., Masullo V., Jani S., Et al., Catheter-based radiotherapy to inhibit restenosis after coronary stenting, N. Engl. J. Med., 336, pp. 1697-1703, (1997)

[8]

Teirstein P.S., Masullo V., Jani S., Et al., A subgroup analysis of the Scripps Coronary Radiation to Inhibit Proliferation Poststenting Trial, Int. J. Radiat. Oncol. Biol. Phys., 42, pp. 1097-1104, (1998)

[9]

Teirstein P.S., Masullo V., Jani S., Et al., Two-year follow-up after catheter based radiotherapy to inhibit coronary restenosis, Circulation, 99, pp. 243-247, (1999)

[10]

Teirstein P.S., Masullo V., Jani S., Et al., Three-year clinical and angiographic follow-up after coronary radiation: Results of a randomized clinical trial, Circulation, 101, pp. 360-365, (2000)

← 1 2 3 4 5 6 7 →